A PHASE 1 STUDY OF DS-3032B IN COMBINATION WITH QUIZARTINIB IN SUBJECTS WITH FLT3-ITD MUTANT ACUTE MYELOID LEUKEMIA THAT ARE RELAPSED/REFRACTORY, OR NEWLY DIAGNOSED AND UNFIT FOR INTENSIVE CHEMOTHERAPY
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Daiichi Sankyo Inc
Start Date
March 13, 2019
End Date
March 31, 2024
Administered By
Duke Cancer Institute
Awarded By
Daiichi Sankyo Inc
Start Date
March 13, 2019
End Date
March 31, 2024